Loading page
Loading page
Loading substance route
Moderately psychologically addictive, particularly with heavy or frequent use. The rapid onset compared to phenibut facilitates compulsive redosing, which is reported to be highly pronounced. The combination of reduced inebriation with greater euphoria relative to other GABAergic depressants contributes to elevated abuse potential.
Physical dependence can develop with regular use over several weeks or longer. Withdrawal symptoms may include severe anxiety, nervousness, tremors, agitation, rapid heartbeat, fatigue, nausea, vomiting, and insomnia. Gradual dose reduction is recommended to avoid withdrawal effects.
Exact lethal dosage is unknown due to limited human usage history. F-Phenibut likely has low toxicity relative to dose when used alone, though precise toxic thresholds have not been established in scientific studies.
Psychosis is reported as a potential withdrawal symptom following cessation of prolonged or heavy use, similar to phenibut. Not typically associated with acute intoxication at standard doses.
F-Phenibut, designated by the developmental code name CGP-11130, is a GABA analogue that was investigated as a potential pharmaceutical agent but was never marketed. The compound belongs to a family of phenyl-substituted GABA derivatives that includes baclofen, tolibut, and phenibut, all of which…
Not scheduled under the Betäubungsmittelgesetz (BtMG). However, sale for human consumption would be regulated under §2 of the Arzneimittelgesetz (Medicines Act). Generally legal when sold as a research chemical or not marketed for consumption.
May be prohibited under the Psychoactive Substances Act 2016, which broadly restricts the production, supply, and importation of psychoactive substances. The Act provides exemptions for alcohol, nicotine, caffeine, and licensed medicinal products, but F-Phenibut does not fall under these exemptions.
Not listed under Buchstabe A, B, C, or D of the controlled substances regulations. Currently considered legal, though this status may be subject to change.